Filing Flows › Health Care › Opko Health (OPK)
Opko Health (OPK) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Opko Health (OPK) Q3 2026 earnings results →
Q3 2026 Revenue up 16% year over year to $65.4M · 82¢ of every $1 of revenue lost · operating margin -48.0%
Opko Health made $65.4M in Q3 2026 (+16% Y/Y): Product $41.8M, License and Service $23.6M. Operating margin -48.0%, net loss $53.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $65.4M in Q3 2026, up 16% year over year and down 60% from the previous quarter. Product was the largest line at 64% of revenue. License and Service added $4.9M year over year (up 26%), 54% of the total change.
Gross margin was 64.3%, up 2.2 points from Q3 2025. Operating costs exceeded revenue by $31.4M, an operating margin of -48.0%. Operating expenses grew 7% against revenue growth of 16%. The fastest-growing cost line was SG&A (+12%). The quarter ended with a net loss of $53.5M, wider than the previous quarter's $8.4M loss. Net interest and other expense of $29.4M was the main reason.
Operating cash flow was −$36.3M. Non-cash charges added back $22.7M of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $7.5M. Capital expenditures of $2.8M exceeded it, leaving free cash flow of −$39.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $65.4M | +16% | -48.0% | −$53.5M | −$36.3M |
| Q2 2026 | 10-Q | Jul 27, 2026 | $164M | +4% | -4.3% | −$8.4M | −$43.5M |
| Q1 2026 | 10-Q | Apr 28, 2026 | $124M | -17% | -41.1% | −$54.8M | −$19.3M |
| Q4 2025 | 10-K | Feb 26, 2026 | $148M | -19% | -25.8% | −$31.3M | −$25.9M |
| Q3 2025 | 10-Q | Oct 29, 2025 | $152M | -13% | 31.7% | $21.6M | −$34.6M |
| Q2 2025 | 10-Q | Jul 31, 2025 | $157M | -14% | -38.3% | −$148M | −$83.4M |
| Q1 2025 | 10-Q | May 1, 2025 | $150M | -14% | -44.8% | −$67.6M | −$34.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Opko Health
We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. (“Pfizer”) for further development and commercialization of Somatrogon (hGH-CTP). Regulatory approvals for Somatrogon (hGH-CTP) for the treatment of children and adolescents as young as three years of age with growth disturbance due to insufficient secretion of growth hormone, have been secured in more than 50 markets worldwide, including in the United States, European Union Member States, Japan, Canada, and Australia under the brand name NGENLA ® . Also, through our pharmaceutical division, we manufacture and sell Rayaldee , a U.S.
In its own words, from its 10-K, filed Mar 3, 2025.
Opko Health against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +16% against the peers' median +10%. Operating margin: -48.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| OPK Opko Health | Q3 2026 | $65.4M | +16% | -48.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Opko Health 10-Q on SEC EDGAR · CIK 944809 · Pharmaceutical Preparations
13F: who owns OPK and who is buying
More on OPK
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results